A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer
The combination of abemaciclib and fulvestrant has promising activity with durable responses in advanced or recurrent endometrial cancer; a randomized trial is planned. See related commentary by Garg and Oza, p. 2073.
Authors
- Alexia Iasonos (ORCID: https://orcid.org/0000-0003-0471-8477)
- Jason Konner
- Vania Hom (ORCID: https://orcid.org/0000-0001-9872-1153)
- William A. Zammarrelli (ORCID: https://orcid.org/0000-0002-9833-3270)
- Pier Selenica (ORCID: https://orcid.org/0000-0003-0086-0513)
- Angela K. Green (ORCID: https://orcid.org/0000-0001-8543-1114)
- Maria M. Rubinstein (ORCID: https://orcid.org/0000-0002-7943-8245)
- Rachel N. Grisham (ORCID: https://orcid.org/0000-0002-8631-9324)
- Iva Petkovska (ORCID: https://orcid.org/0000-0002-4373-6494)
- Lora H. Ellenson (ORCID: https://orcid.org/0000-0001-9127-6982)
- Britta Weigelt (ORCID: https://orcid.org/0000-0001-9927-1270)
- Sarat Chandarlapaty (ORCID: https://orcid.org/0000-0003-4532-8053)
- Joseph P. Erinjeri (ORCID: https://orcid.org/0000-0003-1876-727X)
- Qin Zhou (ORCID: https://orcid.org/0000-0003-1225-2902)
- Carol Aghajanian (ORCID: https://orcid.org/0000-0003-0851-3225)
- Vicky Makker (ORCID: https://orcid.org/0000-0001-9793-7614)
- William P. Tew (ORCID: https://orcid.org/0000-0001-5115-4470)
- Tiffany A. Troso-Sandoval (ORCID: https://orcid.org/0000-0001-7755-7710)
- Jade Loh
- Rashmi Chhetri-Long
- Pooja Shah (ORCID: https://orcid.org/0000-0001-8673-8310)
- Seth Cohen (ORCID: https://orcid.org/0000-0002-4247-8008)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1999
- Citations
- 15
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 6.28